Trelegy Patient Assistance Program
Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) is an inhaler prescribed for adults with asthma or chronic obstructive pulmonary disease. It combines three medications in a single daily dose to reduce inflammation, open airways, and prevent symptom flare-ups.
COPD and asthma both require ongoing medication to keep breathing problems under control. The cost of combination inhalers can be substantial, particularly when insurance doesn’t provide sufficient coverage. Through what are known as Patient Assistance Programs (PAPs), The manufacturer will examine your circumstances and prescription needs when determining who receives program support.
How Prescription Details Affect Trelegy Assistance Eligibility

About the Trelegy Patient Assistance Program
Manufacturers offer assistance for adults managing COPD or asthma who cannot afford their prescribed inhaler. Qualifying means you’ll receive Trelegy through their program, helping keep your airways open and reducing the attacks or exacerbations that make breathing difficult.
Beginning the application process requires a prescription from your pulmonologist or primary care provider. Alongside that, you’ll gather documentation of your household’s yearly income.
Once you’ve collected these materials, Patient Help Network assumes the coordination role. Our team will contact your respiratory specialist to secure the medical confirmations needed, prepare your income records following their specifications, file everything with the manufacturer, and track where your application stands. If you’re approved, the inhaler gets shipped to you directly to your front door.
How Trelegy Works
Airways in COPD and asthma become narrowed by muscle constriction, swelling, and mucus buildup, making it hard to move air in and out of your lungs. Trelegy addresses all three problems simultaneously. Fluticasone reduces swelling and irritation in your airways over time. Umeclidinium relaxes the muscles around airways by blocking receptors that cause them to tighten. Vilanterol keeps airways open for 24 hours.
Having all three in one inhaler means you only need to remember one dose each day instead of using multiple inhalers.
You use Trelegy once daily at roughly the same time, breathing in the powder it releases. Trelegy should not be used more than prescribed. Don’t use it for sudden breathing problems since it’s designed for daily prevention, not rescue. Your doctor might prescribe a separate quick-relief inhaler for emergencies. Effects build gradually, so you may not notice full improvement for several weeks.
Side Effects and Safety Information
Combination inhalers affecting multiple body systems can produce various reactions. Upper respiratory infections like colds happen more often in people using inhaled steroids. Throat pain, hoarseness, or fungal infections in your mouth and throat can develop from the corticosteroid component. Rinsing your mouth after each use helps prevent this.
More concerning reactions need prompt medical attention.
Pneumonia risk increases with inhaled corticosteroids, particularly in COPD patients. Watch for fever, increased mucus production, or worsening shortness of breath. Fast or irregular heartbeat, chest pain, or tremors can result from the long-acting bronchodilator. Vision problems, eye pain, or seeing halos around lights might indicate increased pressure in your eyes.
Bone density can decrease with long-term corticosteroid use. The medication can affect blood sugar, so diabetics should watch their glucose levels more closely. Trelegy is contraindicated in patients with severe hypersensitivity to milk proteins.
Step 1 – Submit Application
Provide basic prescription and household information to begin the application process.
Step 2 – Application Review
Information is reviewed and submitted to appropriate Patient Assistance Programs.
Step 3 – Program Decision
Final eligibility decisions are made by each program. Additional steps or renewals may be required.
PHN will contact you within 24 hours to discuss your situation and help identify appropriate next steps for the application process.
How it applies / Eligibility
Patient assistance programs evaluate applications based on specific eligibility criteria. To be eligible, a person must meet these requirements:
- Single patients earning less than $40,000 per year
- Couples making under $60,000 combined yearly
- Households with three or more people bringing in below $100,000 annually
- Active Trelegy prescription from your healthcare provider
- Proof of U.S. citizenship or legal residency
- Limited or inadequate prescription drug coverage for Trelegy
Income represents only one factor among several that manufacturers consider.
Each program weighs different criteria when deciding who qualifies, and every application gets evaluated individually. Some programs maintain waiting lists depending on available capacity, so applying early improves your chances of timely enrollment.
Frequently asked questions (FAQ`s)
Specific reasons will be provided when they can’t approve applications. Typical causes involve income surpassing their thresholds, existing insurance they view as sufficient, or paperwork that’s incomplete. You can submit a fresh application if your earnings drop, your coverage situation changes, or you locate documents that were missing initially.
Continuing in the program means verifying your eligibility hasn’t changed, which happens annually. You’ll need to show current income and have your doctor confirm you’re still using Trelegy. If you don’t complete this before the deadline, your enrollment ends and you’ll go through the full application process again.
Your application needs a valid prescription for Trelegy written by a licensed provider, records showing total household income for the year, documentation proving citizenship or legal resident status, and details about your prescription drug insurance.
Patient Help Network handles your enrollment completely. We confirm you meet basic requirements, gather every piece of documentation needed, work with your medical providers to obtain approvals, and file applications that are complete and accurate.
No generic version exists currently. The combination of these three specific medications in one inhaler remains available only as brand-name Trelegy, which the program covers for qualifying individuals.
Review duration depends on how many applications are processing and their current staffing for reviews. Patient Help Network maintains communication with the manufacturer about submitted applications and provides updates as your review advances.
The manufacturer can modify program requirements whenever they choose. This might include adjusting income limits, changing what insurance coverage they consider adequate, or revising other qualification factors. Patient Help Network monitors these programs and alerts applicants when changes happen that could affect their eligibility.